Market Overview

FBR Capital Upgrades AMAG Pharmaceuticals To Outperform

Share:
Related AMAG
Mid-Afternoon Market Update: Ariad Pharmaceuticals Surges On Acquisition News; Stage Stores Shares Slide
AMAG Pharmaceuticals Tanks After Raymond James Downgrade

Analysts at FBR Capital upgraded AMAG Pharmaceuticals (NASDAQ: AMAG) from Market Perform to Outperform.

The target price for AMAG Pharmaceuticals has been raised from $21 to $36.

AMAG Pharmaceuticals shares have surged 36.08% over the past 52 weeks, while the S&P 500 index has gained 16.68% in the same period.

AMAG Pharmaceuticals' shares jumped 28.21% to close at $29.72 yesterday.

Latest Ratings for AMAG

DateFirmActionFromTo
Jan 2017Raymond JamesDowngradesMarket PerformUnderperform
Jan 2017Janney CapitalInitiates Coverage OnBuy
Dec 2016Cantor FitzgeraldInitiates Coverage OnNeutral

View More Analyst Ratings for AMAG
View the Latest Analyst Ratings

Posted-In: FBR CapitalUpgrades Analyst Ratings

 

Related Articles (AMAG)

View Comments and Join the Discussion!